Post-trial dopaminergic modulation of conditioned catalepsy: A single apomorphine induced increase/decrease in dopaminergic activation immediately following a conditioned catalepsy response can reverse/enhance a haloperidol conditioned and sensitized catalepsy response

2016 ◽  
Vol 311 ◽  
pp. 87-98 ◽  
Author(s):  
Lucas Rangel Oliveira ◽  
Flávia Regina Cruz Dias ◽  
Breno Garone Santos ◽  
Jade Leal Loureiro Silva ◽  
Robert J. Carey ◽  
...  
2006 ◽  
Author(s):  
Melissa Depenbrock ◽  
Megan Points ◽  
Nathan Downs ◽  
Mark E. Bardgett

2020 ◽  
Author(s):  
Awinita Barpujari ◽  
Michael A Erdek

Aim: Spinal cord stimulation (SCS) is used to clinically manage and/or treat several chronic pain etiologies. A limited amount is known about the influence on patients' use of opioid pain medication. This retrospective analysis evaluated SCS effect on opioid consumption in patients presenting with chronic pain conditions. Materials & methods: Sixty-seven patients underwent a temporary trial device, permanent implant or both. Patients were divided for assessment based on the nature of their procedure(s). Primary outcome was change in morphine equivalent dose (MED), ascertained from preoperative and postoperative medication reports. Results: Postoperative MED was significantly lower in patients who received some form of neuromodulation therapy. Pretrial patients reported an average MED of 41.01 ± 10.23 mg per day while post-trial patients reported an average of 13.30 ± 5.34 mg per day (p < 0.001). Pre-implant patients reported an average MED of 39.14 ± 13.52 mg per day while post-implant patients reported an average MED of 20.23 ± 9.01 mg per day (p < 0.001). There were no significant differences between pre-trial and pre-implant MED, nor between post-trial and post-implant MED. Of the 42 study subjects who reported some amount of pre-intervention opioid use, 78.57% indicated a lower MED (n = 33; p < 0.001), 16.67% indicated no change (n = 7) and 4.76% (n = 2) indicated a higher MED, following intervention. Moreover, SCS therapy resulted in a 26.83% reduction (p < 0.001) in the number of patients with MED >50 mg per day. Conclusion: Spinal cord stimulation may reduce opioid use when implemented appropriately. Neuromodulation may represent alternative therapy for alleviating chronic pain which may avoid a number of deleterious side effects commonly associated with opioid consumption.


1998 ◽  
Vol 350 (1) ◽  
pp. 31-38 ◽  
Author(s):  
James F Flood ◽  
Susan A Farr ◽  
Kayoko Uezu ◽  
John E Morley
Keyword(s):  

2019 ◽  
Vol 179 ◽  
pp. 134-141 ◽  
Author(s):  
Lucas Rangel de Oliveira ◽  
Breno Garone dos Santos ◽  
João Marcos de Mello Bastos ◽  
Richard Ian Samuels ◽  
Robert J. Carey ◽  
...  
Keyword(s):  

1982 ◽  
Vol 5 (1) ◽  
pp. 101
Author(s):  
P.J. Fray ◽  
S.B. Dunnett ◽  
A. Bjorklund ◽  
U. Stenevi ◽  
S.D. Iversen

2012 ◽  
Vol 136 ◽  
pp. S98-S99
Author(s):  
Fabiana da Silva Alves ◽  
Nicole Schmitz ◽  
Nico Abeling ◽  
Johan van der Meer ◽  
Aart Nederveen ◽  
...  

2015 ◽  
Vol 40 (4) ◽  
pp. 414-423 ◽  
Author(s):  
Phillip G. Bell ◽  
Ian H. Walshe ◽  
Gareth W. Davison ◽  
Emma J. Stevenson ◽  
Glyn Howatson

The impact of Montmorency tart cherry (Prunus cerasus L.) concentrate (MC) on physiological indices and functional performance was examined following a bout of high-intensity stochastic cycling. Trained cyclists (n = 16) were equally divided into 2 groups (MC or isoenergetic placebo (PLA)) and consumed 30 mL of supplement, twice per day for 8 consecutive days. On the fifth day of supplementation, participants completed a 109-min cycling trial designed to replicate road race demands. Functional performance (maximum voluntary isometric contraction (MVIC), cycling efficiency, 6-s peak cycling power) and delayed onset muscle soreness were assessed at baseline, 24, 48, and 72 h post-trial. Blood samples collected at baseline, immediately pre- and post-trial, and at 1, 3, 5, 24, 48, and 72 h post-trial were analysed for indices of inflammation (interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor alpha, high-sensitivity C-reactive protein (hsCRP)), oxidative stress (lipid hydroperoxides), and muscle damage (creatine kinase). MVIC (P < 0.05) did not decline in the MC group (vs. PLA) across the 72-h post-trial period and economy (P < 0.05) was improved in the MC group at 24 h. IL-6 (P < 0.001) and hsCRP (P < 0.05) responses to the trial were attenuated with MC (vs. PLA). No other blood markers were significantly different between MC and PLA groups. The results of the study suggest that Montmorency cherry concentrate can be an efficacious functional food for accelerating recovery and reducing exercise-induced inflammation following strenuous cycling exercise.


Sign in / Sign up

Export Citation Format

Share Document